Expressions of PTEN and E-cadherin in breast cancer tissues and their clinical significance

doi:10.3760/cma.j.issn.1673-422X.2019.01.002

Abstract

Abstract: Objective To investigate the expressions of phosphatase and tensin homologue deleted on chromosome ten (PTEN) and epithelial cadherin (E-cadherin) in breast cancer tissues and explore their clinical significance. MethodsWe retrospectively analyzed the clinical data of 263 breast cancer patients admitted to the First Affiliated Hospital of Harbin Medical University from November 2012 to December 2014. The expressions of PTEN and E-cadherin were detected by immunohistochemistry. The relationship of protein expression with clinicopathological characteristics was analyzed by χ2 test or Fisher exact test. Contingency correlation analysis was used to analyze the correlation between PTEN and E-cadherin, and KaplanMeier was used to evaluate the relationship between their expressions and patients′ survival. COX regression model was used to analyze risk factors. ResultsThe positive expression rates of PTEN and Ecadherin in breast cancer tissues were 68.4% (180/263) and 95.4% (251/263) respectively, lower than those in paratumor breast tissues 77.9% (205/263) and 98.5% (259/263), with statistically significant differences (χ2=6.056, P=0.014; χ2=4.125, P=0.042). PTEN expression was associated with lymph node metastasis (χ2=8.443, P=0.015) and clinical stage (χ2=9.253, P=0.010). Ecadherin expression was not correlated with age, menopausal status, tumor maximum diameter, lymph node metastasis and clinical stage (all P>0.05). Contingency correlation analysis showed a positive correlation between PTEN and Ecadherin expressions in breast cancer tissues (C=0.125, P=0.041). Survival analysis showed that the 5 year tumorfree survival rate was 81.9% in the PTEN negative group, lower than 95.0% in the positive group (χ2=12.040, P=0.001). The 5year tumorfree survival rate in the E-cadherin negative group was 66.7%, lower than 92.0% in the positive group (χ2=13.313, P<0.001). COX multivariate analysis showed that negative expressions of PTEN and E-cadherin and lymph node metastasis were independent risk factors for the prognosis of breast cancer patients (HR=2.554, 95%CI: 1.0166.420, P=0.046; HR=3.573, 95%CI: 1.13611.239, P=0.029; HR=3.622, 95%CI: 2.0266.476, P＜0.001). Conclusion PTEN is related to Ecadherin expression and low expressions of both may be one of the mechanisms of breast cancer development, invasion and metastasis. Combined detection can be used as an indicator to determine the prognosis of breast cancer.

Key words: Breast neoplasms, PTEN phosphohydrolase, Cadherins, Prognosis

Chen Yiming, Zhou Yi. Expressions of PTEN and E-cadherin in breast cancer tissues and their clinical significance[J]. Journal of International Oncology, 2019, 46(1): 6-10.

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. ［2］ Zhang Z, Sun L, Zhang Y, et al. Long noncoding RNA FEZF1AS1 promotes breast cancer stemness and tumorigenesis via targeting miR30a/Nanog axis［J］. J Cell Physiol, 2018, 233(11): 8630-8638. DOI: 10.1002/jcp.26611. ［3］ Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta［J］. Cancer Res, 1997, 57(11): 2124-2129. ［4］ Wong SHM, Fang CM, Chuah LH, et al. Ecadherin: its dysregulation in carcinogenesis and clinical implications［J］. Crit Rev Oncol Hematol, 2018, 121: 11-22. DOI: 10.1016/j.critrevonc.2017.11.010. ［5］ Chen CY, Chen J, He L, et al. PTEN: tumor suppressor and metabolic regulator［J］. Front Endocrinol (Lausanne), 2018, 9: 338. DOI: 10.3389/fendo.2018.00338. ［6］ Kechagioglou P, Papi RM, Provatopoulou X, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression［J］. Anticancer Res, 2014, 34(3): 1387-1400. ［7］ Wang LL, Hao S, Zhang S, et al. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases［J］. Hum Pathol, 2017, 61: 49-57. DOI: 10.1016/j.humpath.2016.07.040. ［8］ Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis［J］. Oncotarget, 2017, 8(19): 3204332054. DOI: 10.18632/oncotarget.16761. ［9］ GschwantlerKaulich D, Tan YY, Fuchs EM, et al. PTEN expression as a predictor for the response to trastuzumabbased therapy in Her-2 overexpressing metastatic breast cancer［J］. PLoS One, 2017, 12(3): e0172911. DOI: 10.1371/journal.pone.0172911. ［10］ Mendonsa AM, Na TY, Gumbiner BM. Ecadherin in contact inhibition and cancer［J］. Oncogene, 2018, 37(35): 4769-4780. DOI: 10.1038/s41388-018-0304-2. ［11］ Li Z, Yin S, Zhang L, et al. Prognostic value of reduced Ecadherin expression in breast cancer: a metaanalysis［J］. Oncotarget, 2017, 8(10): 16445-16455. DOI: 10.18632/oncotarget.14860. ［12］谢莉莉, 王东林. 乳腺癌患者HER-2、PCNA和E-cadherin蛋白表达及临床病理特征与预后的相关性［J］. 现代肿瘤医学, 2017, 25(18): 2929-2934. DOI: 10.3969/j.issn.1672-4992.2017.18.019. ［13］谭敏华, 雷伟华, 谭冬玲, 等. 浸润性乳腺癌ER、PR、HER2、Ecadherin、CK5/6检测与临床预后关系［J］. 临床与实验病理学杂志, 2011, 27(9): 933938. DOI: 10.3969/j.issn.10017399.2011.09.004. ［14］ Memni H, Macherki Y, Klayech Z, et al. Ecadherin genetic variants predict survival outcome in breast cancer patients［J］. J Transl Med, 2016, 14(1): 320. DOI: 10.1186/s12967-016-1077-4. ［15］ Li Z, Wang L, Zhang W, et al. Restoring Ecadherinmediated cellcell adhesion increases PTEN protein level and stability in human breast carcinoma cells［J］. Biochem Biophys Res Commun, 2007, 363(1): 165-170. DOI: 10.1016/j.bbrc.2007.08.154. ［16］ Asproni P, Ressel L, Millanta F, et al. Colocalization of PTEN and Ecadherin in canine mammary hyperplasias and benign and malignant mammary tumors［J］. Res Vet Sci, 2015, 103: 113-118. DOI: 10.1016/j.rvsc.2015.09.022.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[10]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.